Gender issues in antiepileptic drug treatment

Neurobiology of Disease

Volumn 72, Issue PB, 2014, Pages 217-223

  Perucca, Emilio ^a,d   Battino, Dina ^b   Tomson, Torbjörn ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antiepileptic drugs; Epilepsy; Gender; Menopause; Pharmacokinetics; Pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; CONTRACEPTIVE AGENT; ESTROGEN; GESTAGEN; GLUCURONOSYLTRANSFERASE 1A4; SEX HORMONE; VALPROIC ACID;

ADVERSE OUTCOME; ALTERNATIVE MEDICINE; CONTRACEPTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG USE; EPILEPSY; GENDER; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; MENSTRUAL CYCLE; NONHUMAN; PERINATAL DRUG EXPOSURE; PREGNANCY; REVIEW; SEIZURE; SEX DIFFERENCE; FEMALE; MALE; SEXUAL DEVELOPMENT;

ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; MALE; PREGNANCY; SEX CHARACTERISTICS;

EID: 84909980035     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.05.011     Document Type: Review

References (83)

1. Adab N., Kini U., Vinten J., Ayres J., Baker G., Clayton-Smith J., et al. The longer term outcome of children born to mothers with epilepsy. J. Neurol. Neurosurg. Psych. 2004, 75:1575-1583.
2. Bäckström T., Jorpes P. Serum phenytoin, phenobarbital, carbamazepine, albumin; and plasma estradiol, progesterone concentrations during the menstrual cycle in WWE. Acta Neurol. Scand. 1979, 59(2-3):63-71.
3. Barcs G., Walker E.B., Elger C.E., Scaramelli A., Stefan H., Sturm Y., et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000, 41:1597-1607.
4. Battino D., Binelli S., Bossi L., Como M.L., Croci D., Cusi C., et al. Changes in primidone/phenobarbitone ratio during pregnancy and the puerperium. Clin. Pharmacokinet. 1984, 9:252-260.
5. Battino D., Tomson T., Bonizzoni E., Craig J., Lindhout D., Sabers A., et al. EURAP Study Group. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia 2013, 54:405-414.
6. Bauer J., Isojärvi J.I., Herzog A.G., Reuber M., Polson D., Taubøll E., et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J. Neurol. Neurosurg. Psych. 2002, 73:121-125.
7. Beghi E., Beghi M. Gender differences in epidemiology and comorbidities of epilepsy. Epilepsy in Women 2013, 1-10. Wiley-Blackwell, Chichester, UK. C.L. Harden, S.V. Thomas, T. Tomson (Eds.).
8. Bockbrader H.N., Burger P., Knapp L., Corrigan B.W. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia 2011, 52:248-257.
9. Boruban M.C., Yasar U., Babaoglu M.O., Sencan O., Bozkurt A. Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J. Chemother. 2006, 18:421-424.
10. Brodie M.J., Mintzer S., Pack A.M., Gidal B.E., Vecht C.J., Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern?. Epilepsia 2013, 54:11-27.
11. Bromley R.L., Mawer G.E., Briggs M., Cheyne C., Clayton-Smith J., García-Fiñana M., et al. Liverpool and Manchester Neurodevelopment Group. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J. Neurol. Neurosurg. Psych. 2013, 84(6):637-643. (Jun).
12. Christensen J., Sabers A., Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006, 67(8):1497-1499. (Oct 24).
13. Christensen J., Grønborg T.K., Sørensen M.J., Schendel D., Parner E.T., Pedersen L.H., et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309(16):1696-1703. (Oct).
14. Cialis Summary of Product Characteristics 2013, Eli Lilly and Co Ltd, Basingstoke, UK, http://www.medicines.org.uk/emc/medicine/11363#INTERACTIONS (last accessed December 3, 2013).
15. Contin M., Albani F., Ambrosetto G., Avoni P., Bisulli F., Riva R., et al. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia 2006, 47:1573-1575.
16. de Haan G.J., Edelbroek P., Segers J., Engelsman M., Lindhout D., Devile-Notschaele M., et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004, 63(3):571-573. (2013a).
17. Fattore C., Perucca E. Novel medications for epilepsy. Drugs 2011, 71:2151-2178.
18. Gaffield M.E., Culwell K.R., Lee C.R. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception 2011, 83(1):16-29. (Oct).
19. Galimberti C.A., Mazzucchelli I., Arbasino C., Canevini M.P., Fattore C., Perucca E. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. Epilepsia 2006, 47:1569-1572.
20. Greenblatt D.J., Divoll M., Puri S.K., Ho I., Zinny M.A., Shader R.I. Clobazam kinetics in the elderly. Br. J. Clin. Pharmacol. 1981, 12(5):631-636.
21. Hernandez-Diaz S., Smith C.R., Shen A., Mittendorf R., Hauser W.A., Yerby M., et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012, 78:1692-1699.
22. Herzog A.G. Catamenial epilepsy: definition, prevalence, pathophysiology and treatment. Seizure 2008, 17:151-159.
23. Herzog A.G., Drislane F.W., Schomer D.L., Pennell P.B., Bromfield E.B., Dworetzky B.A., et al. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology 2005, 65:1016-1020.
24. Herzog A.G., Drislane F.W., Schomer D.L., Pennell P.B., Bromfield E.B., Dworetzky B.A., et al. Differential effects of antiepileptic drugs on neuroactive steroids in men with epilepsy. Epilepsia 2006, 47:1945-1948.
25. Herzog A.G., Blum A.S., Farina E.L., Maestri X.E., Newman J., Garcia E., et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009, 72:911-914.
26. Herzog A.G., Fowler K.M., Smithson S.D., Kalayjian L.A., Heck C.N., Sperling M.R., et al. Progesterone Trial Study Group. Progesterone vs placebo therapy for women with epilepsy: a randomized clinical trial. Neurology 2012, 78:1959-1966.
27. Hitiris N., Barrett J.A., Brodie M.J. Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: five case reports. Epilepsy Behav. 2006, 8:418-421.
28. Hu X., Wang J., Dong W., Fang Q., Hu L., Liu C. A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res. 2011, 97:73-82.
29. Ibarra M., Vázquez M., Fagiolino P., Derendorf H. Sex related differences on valproic acid pharmacokinetics after oral single dose. J. Pharmacokinet. Pharmacodyn. 2013, 40(4):479-486.
30. Johannessen Landmark C., Johannessen S.I., Tomson T. Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. Adv. Drug Deliv. Rev. 2012, 64:896-910.
31. Kalthoff S., Winkler A., Freiberg N., Manns M.P., Strassburg C.P. Gender matters: estrogen receptor alpha (ERα) and histone deacetylase (HDAC) 1 and 2 control the gender-specific transcriptional regulation of human uridine diphosphate glucuronosyltransferases genes (UGT1A). J. Hepatol. 2013, 59(4):797-804. (Oct).
32. Lossius M.I., Tauboll E., Mowinckel P., Morkrid L., Gjerstad L. Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy-a prospective randomized double-blind withdrawal study. Epilepsia. 2007, 48:1875-1882.
33. Marino S.E., Birnbaum A.K., Leppik I.E., Conway J.M., Musib L.C., Brundage R.C., et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin. Pharmacol. Ther. 2012, 91(3):483-488.
34. Markoula S., Teotonio R., Ratnaraj N., Duncan J.S., Sander J.W., Patsalos P.N. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. Ther. Drug Monit. 2014, (Feb 19 [Epub ahead of print]).
35. Mawhinney E., Campbell J., Craig J., Russell A., Smithson W., Parsons L., et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?. Seizure 2012, 21(3):215-218. (Mar).
36. Mazzucchelli I., Onat F.Y., Ozkara C., Atakli D., Specchio L.M., Neve A.L., et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006, 47(3):504-509. (Mar).
37. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., et al. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 2009, 360:1597-1605.
38. Meador K.J., Baker G.A., Browning N., Cohen M.J., Bromley R.L., Clayton-Smith J., NEAD Study Group, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6years (NEAD study): a prospective observational study. Lancet Neurol. 2013, 12(3):244-252. (Mar).
39. Mikkonen K., Vainionpää L.K., Pakarinen A.J., Knip M., Järvelä I.Y., Tapanainen J.S., et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 2004, 62:445-450.
40. Morrell M.J., Flynn K.L., Done S., Flaster E., Kalayjian L., Pack A.M. Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav. 2005, 6:360-365.
41. Morrell M.J., Hayes F.J., Sluss P.M., Adams J.M., Bhatt M., Ozkara C., et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann. Neurol. 2008, 64:200-211.
42. Motta E., Golba A., Ostrowska Z., Steposz A., Huc M., Kotas-Rusnak J., et al. Progesterone therapy in women with epilepsy. Pharmacol. Rep. 2013, 65:89-98.
43. Najafi M., Sadeghi M.M., Mehvari J., Zare M., Akbari M. Progesterone therapy in women with intractable catamenial epilepsy. Adv. Biomed. Res. 2013, 2:8. (Mar). 10.4103/2277-9175.107974.
44. O'Brien M.D., Guillebaud J. Contraception for women taking antiepileptic drugs. J. Fam. Plann. Reprod. Health Care 2010, 36:239-242.
45. Ohman I., Vitols S., Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000, 41(6):709-713. (Jun).
46. Ohman I., Luef G., Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure 2008, 17:199-202.
47. Ohman I., Sabers A., de Flon P., Luef G., Tomson T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Res. 2009, 87:124-129.
48. Pack A.M., Morrell M.J., Randall A., McMahon D.J., Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008, 70:1586-1593.
49. Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs). Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin. Pharmacokinet. 2013, 52:1045-1061.
50. Pennell P.B., Newport D.J., Stowe Z.N., Helmers S.L., Montgomery J.Q., Henry T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology. 2004, 62:292-295.
51. Pennell P.B., Peng L., Newport D.J., Ritchie J.C., Koganti A., Holley D.K., et al. Lamotrigine in pregnancy. Clearance, therapeutic drug monitoring and seizure frequency. Neurology 2008, 70(22 Pt 2):2130-2136. (May 27).
52. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. 2006, 61:246-255.
53. Perucca E., Cloyd J., Critchley D., Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008, 49:1123-1141.
54. Petrenaite V., Sabers A., Hansen-Schwartz J. Seizure deterioration in women treated with oxcarbazepine during pregnancy. Epilepsy Res. 2009, 84:245-249.
55. Petrenaite V., Sabers A., Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 2005, 65(3):185-188. (Jul).
56. Reddy D.S. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res. 2009, 85:1-30.
57. Reimers A., Helde G., Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005, 46:1414-1417.
58. Reimers A., Brodtkorb E., Helde G., Spigset O. Lamotrigine serum concentrations throughout the menstrual cycle-a study of 2 cases. Clin. Neuropharmacol. 2006, 29:160-162.
59. Reimers A., Helde G., Bråthen G., Brodtkorb E. Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. Epilepsy Res. 2011, 94:198-205.
60. Rosciszewska D., Buntner B., Guz I., Zawisza L. Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in WWE. J. Neurol. Neurosurg. Psychiatry 1986, 49:47-51.
61. Sabers A., Buchholt J.M., Uldall P., Hansen E.L. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001, 47:151-154.
62. Sake J.K., Hebert D., Isojarvi J., Doty P., De Backer M., Davies K., et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010, 24:1055-1068.
63. Shallcross R., Bromley R.L., Irwin B., Bonnett L.J., Morrow J., Baker G.A. Liverpool Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011, 76(4):383-389. (Jan 25).
64. Sidhu J., Job S., Singh S., Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol. 2006, 61:191-199.
65. Smith G.A., McKauge L., Dubetz D., Tyrer J.H., Eadie M.J. Factors influencing plasma concentrations of ethosuximide. Clin. Pharmacokinet. 1979, 4(1):38-52.
66. Stevens S.J., Harden C.L. Hormonal therapy for epilepsy. Curr Neurol Neurosci Rep. 2011, 11:435-442.
67. Tomson T., Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012, 11:803-813.
68. Tomson T., Lindbom U., Ekqvist B., Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994, 35:122-130.
69. Tomson T., Luef G., Sabers A., Pittschieler S., Ohman I. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006, 67:1297-1299.
70. Tomson T., Palm R., Kallen K., Ben-Menachem E., Soderfeldt B., Danielsson B., Johansson R., Luef G., Ohman I. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007, 48:1111-1116.
71. Tomson T., Lukic S., Ohman I. Are lamotrigine kinetics altered in menopause? Observations from a drug monitoring database. Epilepsy Behav. 2010, 19:86-88.
72. Tomson T., Battino D., Bonizzoni E., et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011, 10:609-617.
73. Tomson T., Johannessen Landmark C., Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013, 54:405-414.
74. Tran T.A., Leppik I.E., Blesi K., Sathanandan S.T., Remmel R. Lamotrigine clearance during pregnancy. Neurology 2002 Jul 23, 59(2):251-255.
75. van den Heuvel M.W., van Bragt A.J., Alnabawy A.K., Kaptein M.C. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005, 72(3):168-174. (Jan 25).
76. Verrotti A., D'Egidio C., Mohn A., Coppola G., Parisi P., Chiarelli F. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011, 52:199-211.
77. Walzer M., Bekersky I., Blum R.A., Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy 2012, 32:340-353.
78. Wegner I., Edelbroek P.M., Bulk S., Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology 2009 Oct 27, 73(17):1388-1393.
79. Wegner I., Wilhelm A.J., Sander J.W., Lindhout D. The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav 2013 Oct, 29(1):217-221.
80. Wegner I., Wilhelm A.J., Lambrechts D.A., Sander J.W., Lindhout D. Effect of oral contraceptives on lamotrigine levels depends on comedication. Acta Neurol. Scand. 2013, (Nov 8, Epub ahead of print). 10.1111/ane.12197.
81. Westin A.A., Reimers A., Helde G., Nakken K.O., Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 2008, 17:192-198.
82. Westin A.A., Nakken K.O., Johannessen S.I., Reimers A., Lillestolen K.M., Brodtkorb E. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia 2009, 50:480-485.
83. Yerby M.S., Friel P.N., McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992, 42:12-16.